<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03927924</url>
  </required_header>
  <id_info>
    <org_study_id>CRE 2018.556</org_study_id>
    <nct_id>NCT03927924</nct_id>
  </id_info>
  <brief_title>High-intensity Focused Ultrasound Study</brief_title>
  <official_title>Evaluation of the Effectiveness of High-intensity Focused Ultrasound for the Treatment of Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Conventional treatment options for localized prostate cancer include prostatectomy,&#xD;
      radiotherapy and active surveillance. However, prostatectomy and radiotherapy carry certain&#xD;
      degree of morbidity, including the risks of urinary incontinence, erectile dysfunction and&#xD;
      injury to the structures in the proximity. Active surveillance carries the risk of disease&#xD;
      progression and psychological distress to the patients. Focal therapy employs the concept of&#xD;
      only destroying the significant lesion, resulting in disease cure and improved functional&#xD;
      outcome. Among the different options of focal therapy, high-intensity focused ultrasound&#xD;
      (HIFU) is one of the most commonly employed energy sources. It exerts its effect through&#xD;
      thermal and mechanical destruction of cancer tissue. This study aims at assess the&#xD;
      effectiveness of such treatment in prostate cancer management.&#xD;
&#xD;
      In this study, investigators evaluate the early oncological outcome and objective functional&#xD;
      outcome of patients undergoing HIFU for the treatment of localized intermediate risk prostate&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    due to funding&#xD;
  </why_stopped>
  <start_date type="Actual">June 25, 2019</start_date>
  <completion_date type="Actual">January 28, 2021</completion_date>
  <primary_completion_date type="Actual">January 28, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absence of Prostate Cancer on Biopsy</measure>
    <time_frame>3 months</time_frame>
    <description>Oncological outcome 1: percentage in absence of prostate cancer on biopsy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Urodynamic</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Functional outcome 1: change in urodynamic function assessed by flowrate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urinating Symptom Score</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Functional outcome 2: change in total scores in International Prostate Symptom Score (IPSS) questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Significant Prostate Cancer</measure>
    <time_frame>3 months</time_frame>
    <description>Oncological outcome 2: presence of significant prostate cancer, defined by presence of Gleason score (ranges from 6 to 10) equals or more than 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Prostate specific antigen (PSA)</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Oncological outcome 3: PSA change after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score</measure>
    <time_frame>Post treatment (day 1)</time_frame>
    <description>Post-treatment pain score ranges from 1 to 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Prostate Symptom Score</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Functional outcome 3: change in symptom scores in EPIC-26 questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>High-intensity focused ultrasound</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>High-intensity focused ultrasound</intervention_name>
    <description>Energy employed to exert its effect through thermal and mechanical destruction of cancer tissue</description>
    <arm_group_label>High-intensity focused ultrasound</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Visible index lesion(s) on MRI&#xD;
&#xD;
          -  Index lesion(s) greater than 0.5 cm3&#xD;
&#xD;
          -  Found to have localized low-risk or intermediate-risk prostate cancer after MRI-USG&#xD;
             fusion targeted biopsy and saturation biopsy:&#xD;
&#xD;
               1. Clinical tumour stage T2, or&#xD;
&#xD;
               2. Gleason score 7, or&#xD;
&#xD;
               3. PSA 20 ng/ml&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prostate size larger than 50 ml&#xD;
&#xD;
          -  Patients unfit for contrast MRI exam&#xD;
&#xD;
          -  Patients with previous treatment of prostate cancer&#xD;
&#xD;
          -  Patients with previous surgery on the prostate&#xD;
&#xD;
          -  Patients with active urinary tract infection&#xD;
&#xD;
          -  Patients with bladder pathology including bladder stone and bladder cancer&#xD;
&#xD;
          -  Patients with urethral stricture&#xD;
&#xD;
          -  Patients with neurogenic bladder and/or sphincter abnormalities&#xD;
&#xD;
          -  Fail to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only man will develop prostate cancer</gender_description>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 22, 2019</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2019</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Chi Hang Yee</investigator_full_name>
    <investigator_title>Honorary Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Focal Therapy</keyword>
  <keyword>High-intensity focused ultrasound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

